Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 3/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488317 | 0.84 | P4HTM (0.53) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL2300999 | 0.84 | P4HTM (0.53) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL30489408 | 0.83 | KMT2A (0.57) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL18113755 | 0.82 | MEN1 (0.46) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL796465 | 0.81 | MAPK1 (0.57) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| Potassium Ion SCHEMBL796078 | 0.81 | KMT2A (0.45) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL20271034 | 0.77 | KMT2A (0.41) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL18442520 | 0.77 | KMT2A (0.41) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL11192069 | 0.77 | DRD3 (0.46) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL17668487 | 0.76 | LMNA (0.42) | KMT2AABL1BACE1BACE2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103221408-A | Triazine-oxadiazole compounds | NOVARTIS AG | 2013-07-24 | — | — | CN | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | MEN1 4842/4885KMT2A 3938/4885NPC1 3204/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | MEN1 4842/4885KMT2A 3938/4885NPC1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.